IRD
IRD clinical trials: Opus Genetics, Inc.
Every trial on ClinicalTrials.gov where Opus Genetics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 17
- Trials linked
- 17
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IRD on the catalyst calendar · IRD registry changes
- Primary completion Dec 2032Sponsor estimatePhase 1/Phase 2NCT07681778Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)Opus Genetics, Inc · Leber Congenital AmaurosisRecruitingIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 11, 2023ActualPhase 3NCT05646719Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With PresbyopiaOpus Genetics, Inc · PresbyopiaCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 18, 2022ActualPhase 3NCT05223478Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric SubjectsOpus Genetics, Inc · MydriasisCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 18, 2022ActualPhase 3NCT05134974Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)Opus Genetics, Inc · MydriasisCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 25, 2023ActualPhase 2NCT04692688Study of the Safety and Efficacy of APX3330 in Diabetic RetinopathyOpus Genetics, Inc · Diabetic RetinopathyCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 17, 2021ActualPhase 2NCT04675151Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With PresbyopiaOpus Genetics, Inc · PresbyopiaCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 19, 2022ActualPhase 3NCT04638660Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision DisturbancesOpus Genetics, Inc · Dim Light Vision DisturbancesCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 23, 2020ActualPhase 3NCT04620213Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced MydriasisOpus Genetics, Inc · MydriasisCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 17, 2019ActualPhase 2NCT04024891Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced MydriasisOpus Genetics, Inc · MydriasisCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2007ActualPhase 2NCT04004507Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision DisturbancesOpus Genetics, Inc · Decrease in Night VisionCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2019ActualPhase 2NCT03960866Safety and Efficacy of Ophthalmic Phentolamine Mesylate in GlaucomaOpus Genetics, Inc · Open Angle GlaucomaCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 16, 2012ActualPhase 2NCT01703559The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision DisturbancesOpus Genetics, Inc · Night Vision ComplaintsCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 3NCT07140783OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic...Opus Genetics, Inc · Vision Loss NightRecruitingIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 3, 2025ActualPhase 3NCT06542497Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With PresbyopiaOpus Genetics, Inc · PresbyopiaCompletedIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 17, 2025ActualPhase 3NCT06349759Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual DisturbancesOpus Genetics, Inc · Mesopic VisionCompletedIRDLeadVTRSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2030Sponsor estimatePhase 1/Phase 2NCT07185256Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or...Opus Genetics, Inc · ARBRecruitingIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2028Sponsor estimatePhase 1/Phase 2NCT05616793Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm...Opus Genetics, Inc · LCA5RecruitingIRDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 17 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner